Enzo Biochem (ENZ) 10-K2019 FY Annual report

Filed: 15 Oct 19, 4:56pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: adequacy, al, anin, approvalof, arbitration, Babylon, banc, bargaining, bodily, bothin, Brexit, California, carcinoma, Century, Citibank, clarify, clinician, Coinsurance, collateral, Commonwealth, constrain, contend, CT, CY, cycle, deposit, dialogue, Dickenson, driven, easement, eighteen, EKRA, evolution, expedient, Florida, formal, formally, geography, goal, gonorrhea, grandfathering, HBV, HCC, hepatocellular, hindsight, HIPPA, hospital, implicated, inflammation, inhibitor, inpatient, Island, joined, kinase, land, lipid, liver, Maryland, men, mid, mortgage, mortgagee, mortgagor, NG, novo, onAMPIPROBE, oncology, outcome, outlined, outpatient, outreach, overpaid, Ozanimod, package, paper, passage, path, Pennsylvania, pharangeal, phosphorylating, pilot, preauthorization, pressure, proliferation, prostate, PTAB, question, recordkeeping, recoup, rectal, rehearingen, remitted, resistance, revaluation, Rhode, rigid, scalable, send, speedier, sphingosine, spur, STI, stressed, strike, tangible, tenant, thede, thereported, Town, transformative, transparency, trend, tumor, twointer, Union, unpatentable, variance, VCU, Vimentin, Virginia, vivo, withdrew, withhold, xenotransplantation

Removed: abatement, accountable, activation, Agilent, alleged, allegedly, amend, anabolic, ANSI, antisense, assistance, attributed, begin, billable, capita, charging, chromosomal, coalition, commenced, comment, complaint, conferred, configuration, construct, construction, consulting, contact, contest, contested, creation, DC, declaratory, declined, demonstration, disclose, docking, dropped, eligibility, elimination, emerging, escrow, examine, exchanged, excise, exhausted, expenditure, expert, expressly, Eye, facilitating, falling, floor, forced, franc, functionally, gained, Gaithersburg, genome, glycolipid, highest, immunomodulation, inactivated, inconsistency, inconsistent, induction, insertional, interaction, interpret, IPAB, lawsuit, LDT, lien, localization, map, metabolism, MidCap, missing, month, motion, moved, mutated, nominal, noncompliance, nuclear, ordered, preempt, prepaid, presently, preserving, promise, promotion, rebase, rectify, resolved, responded, restrict, ruling, setting, shipped, show, specificity, sterling, structural, supersede, synthesize, technically, transduction, unbilled, uncollectable, uncollected, updated, validate, vector, verification, vigorously, virtual, wild, worth, wrongful

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ENZ transcripts

ENZ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32 (a)

CERTIFICATE PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Enzo Biochem, Inc., and Subsidiaries (“the Company”) on Form 10-K for the fiscal year ended July 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Elazar Rabbani, Ph.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: October 15, 2019
	By:	/s/ Elazar Rabbani, Ph.D.
		Elazar Rabbani, Ph.D.
		Chairman of the Board, Chief Executive Officer and Director

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Act Commission or its staff upon request.